Exelixis, Inc. (EX9.DE)
EUR 32.28
(1.22%)
EUR 32.28
(1.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 196.6 Million USD | -2.42% |
| 2022 | 222.35 Million USD | -29.71% |
| 2021 | 300.29 Million USD | 160.46% |
| 2020 | 119.2 Million USD | -70.21% |
| 2019 | 369.47 Million USD | -18.28% |
| 2018 | 444.87 Million USD | 170.35% |
| 2017 | 167.22 Million USD | 848.31% |
| 2016 | -22.34 Million USD | 81.37% |
| 2015 | -119.96 Million USD | 43.55% |
| 2014 | -212.52 Million USD | -7.18% |
| 2013 | -198.27 Million USD | -87.83% |
| 2012 | -107.75 Million USD | -204.38% |
| 2011 | 101.13 Million USD | 310.82% |
| 2010 | -47.97 Million USD | 60.16% |
| 2009 | -120.39 Million USD | 28.95% |
| 2008 | -169.44 Million USD | 22.83% |
| 2007 | -219.58 Million USD | -99.91% |
| 2006 | -109.84 Million USD | -44.09% |
| 2005 | -76.23 Million USD | -25.98% |
| 2004 | -60.5 Million USD | 21.68% |
| 2003 | -77.26 Million USD | -10.43% |
| 2002 | -69.96 Million USD | -58.76% |
| 2001 | -44.06 Million USD | -412.83% |
| 2000 | 14.08 Million USD | 207.53% |
| 1999 | -13.1 Million USD | 14.36% |
| 1998 | -15.29 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 101.51 Million USD | -22.24% |
| 2023 FY | - USD | -2.42% |
| 2023 Q3 | -17.58 Million USD | -120.96% |
| 2023 Q2 | 83.89 Million USD | 190.98% |
| 2023 Q1 | 28.83 Million USD | 159.97% |
| 2023 Q4 | 88.31 Million USD | 602.27% |
| 2022 Q4 | -48.07 Million USD | -154.46% |
| 2022 Q3 | 88.27 Million USD | -0.23% |
| 2022 Q2 | 88.48 Million USD | 6.29% |
| 2022 Q1 | 83.24 Million USD | -28.63% |
| 2022 FY | - USD | -29.71% |
| 2021 FY | - USD | 160.46% |
| 2021 Q3 | 56.42 Million USD | -55.46% |
| 2021 Q2 | 126.67 Million USD | 9279.42% |
| 2021 Q1 | -1.38 Million USD | -105.68% |
| 2021 Q4 | 116.64 Million USD | 106.72% |
| 2020 Q1 | 54.98 Million USD | -28.88% |
| 2020 Q2 | 77.73 Million USD | 41.38% |
| 2020 Q3 | -40.22 Million USD | -151.75% |
| 2020 Q4 | 24.29 Million USD | 160.4% |
| 2020 FY | - USD | -70.21% |
| 2019 Q2 | 94.68 Million USD | 11.97% |
| 2019 FY | - USD | -18.28% |
| 2019 Q4 | 77.31 Million USD | -34.7% |
| 2019 Q3 | 118.4 Million USD | 25.05% |
| 2019 Q1 | 84.55 Million USD | -27.34% |
| 2018 Q1 | 118.37 Million USD | 204.15% |
| 2018 Q4 | 116.37 Million USD | -10.93% |
| 2018 FY | - USD | 170.35% |
| 2018 Q2 | 89.2 Million USD | -24.64% |
| 2018 Q3 | 130.65 Million USD | 46.47% |
| 2017 Q3 | 84.86 Million USD | 193.08% |
| 2017 Q2 | 28.95 Million USD | 34.29% |
| 2017 Q4 | 38.91 Million USD | -54.14% |
| 2017 FY | - USD | 848.31% |
| 2017 Q1 | 21.56 Million USD | -45.79% |
| 2016 Q4 | 39.77 Million USD | 283.34% |
| 2016 Q2 | -23.13 Million USD | 52.4% |
| 2016 Q1 | -48.61 Million USD | -54.64% |
| 2016 Q3 | 10.37 Million USD | 144.85% |
| 2016 FY | - USD | 81.37% |
| 2015 Q3 | -34.84 Million USD | -17.71% |
| 2015 Q2 | -29.6 Million USD | -29.3% |
| 2015 Q1 | -22.89 Million USD | 45.74% |
| 2015 FY | - USD | 43.55% |
| 2015 Q4 | -31.43 Million USD | 9.79% |
| 2014 FY | - USD | -7.18% |
| 2014 Q4 | -42.19 Million USD | 5.4% |
| 2014 Q3 | -44.59 Million USD | 26.16% |
| 2014 Q2 | -60.4 Million USD | 3.07% |
| 2014 Q1 | -62.31 Million USD | -5.88% |
| 2013 Q3 | -55.55 Million USD | -12.18% |
| 2013 Q2 | -49.52 Million USD | -51.41% |
| 2013 FY | - USD | -87.83% |
| 2013 Q1 | -32.71 Million USD | -3.21% |
| 2013 Q4 | -58.85 Million USD | -5.94% |
| 2012 Q4 | -31.69 Million USD | -38.03% |
| 2012 FY | - USD | -204.38% |
| 2012 Q1 | -21.09 Million USD | -136.83% |
| 2012 Q2 | -29.81 Million USD | -41.29% |
| 2012 Q3 | -22.96 Million USD | 22.98% |
| 2011 FY | - USD | 310.82% |
| 2011 Q1 | -12.26 Million USD | -156.42% |
| 2011 Q2 | -19.03 Million USD | -55.18% |
| 2011 Q3 | 83.84 Million USD | 540.43% |
| 2011 Q4 | 57.29 Million USD | -31.67% |
| 2010 Q4 | -4.78 Million USD | -227.0% |
| 2010 Q1 | -16.75 Million USD | 38.04% |
| 2010 FY | - USD | 60.16% |
| 2010 Q2 | -13.01 Million USD | 22.28% |
| 2010 Q3 | -1.46 Million USD | 88.76% |
| 2009 Q1 | -33.48 Million USD | 3.65% |
| 2009 Q4 | -27.03 Million USD | -64.2% |
| 2009 Q3 | -16.46 Million USD | 52.27% |
| 2009 Q2 | -34.49 Million USD | -2.99% |
| 2009 FY | - USD | 28.95% |
| 2008 Q2 | -45.38 Million USD | -4.45% |
| 2008 Q1 | -43.45 Million USD | 42.72% |
| 2008 FY | - USD | 22.83% |
| 2008 Q4 | -34.75 Million USD | 24.18% |
| 2008 Q3 | -45.84 Million USD | -1.0% |
| 2007 Q2 | -35.84 Million USD | -17.42% |
| 2007 Q3 | -77.34 Million USD | -115.77% |
| 2007 Q1 | -30.52 Million USD | -1.32% |
| 2007 Q4 | -75.86 Million USD | 1.91% |
| 2007 FY | - USD | -99.91% |
| 2006 Q2 | -25.75 Million USD | 2.75% |
| 2006 Q4 | -30.13 Million USD | -9.75% |
| 2006 Q3 | -27.45 Million USD | -6.62% |
| 2006 Q1 | -26.47 Million USD | -6.27% |
| 2006 FY | - USD | -44.09% |
| 2005 Q1 | -22.68 Million USD | -471.64% |
| 2005 Q4 | -24.91 Million USD | -6.83% |
| 2005 FY | - USD | -25.98% |
| 2005 Q2 | -5.3 Million USD | 76.6% |
| 2005 Q3 | -23.32 Million USD | -339.39% |
| 2004 FY | - USD | 21.68% |
| 2004 Q3 | -22.5 Million USD | -10.69% |
| 2004 Q4 | 6.1 Million USD | 127.12% |
| 2004 Q2 | -20.33 Million USD | 11.5% |
| 2004 Q1 | -22.97 Million USD | -30.08% |
| 2003 Q4 | -17.66 Million USD | 9.11% |
| 2003 Q3 | -19.43 Million USD | 7.22% |
| 2003 Q2 | -20.94 Million USD | -9.03% |
| 2003 Q1 | -19.21 Million USD | -41.49% |
| 2003 FY | - USD | -10.43% |
| 2002 FY | - USD | -58.76% |
| 2002 Q4 | -13.57 Million USD | 29.68% |
| 2002 Q3 | -19.31 Million USD | 5.36% |
| 2002 Q2 | -20.4 Million USD | -29.66% |
| 2002 Q1 | -15.73 Million USD | -7.5% |
| 2001 Q4 | -14.63 Million USD | -27.53% |
| 2001 FY | - USD | -412.83% |
| 2001 Q2 | -5.35 Million USD | 44.9% |
| 2001 Q1 | -9.72 Million USD | -19.19% |
| 2001 Q3 | -11.47 Million USD | -114.3% |
| 2000 Q3 | -6.2 Million USD | 3.14% |
| 2000 FY | - USD | 207.53% |
| 2000 Q1 | -3.23 Million USD | 0.0% |
| 2000 Q2 | -6.41 Million USD | -98.45% |
| 2000 Q4 | -8.15 Million USD | -31.36% |
| 1999 FY | - USD | 14.36% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| BioNTech SE | 1.08 Billion EUR | 81.923% |
| CureVac N.V. | -234.09 Million EUR | 183.986% |
| Biotest Aktiengesellschaft | 179 Million EUR | -9.834% |
| Biotest Aktiengesellschaft | 179 Million EUR | -9.834% |
| BRAIN Biotech AG | -2.38 Million EUR | 8336.364% |
| Formycon AG | 81.05 Million EUR | -142.56% |
| Heidelberg Pharma AG | -18.7 Million EUR | 1150.989% |
| Medigene AG | -14.58 Million EUR | 1447.974% |